ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
ICR awarded prestigious prize for transformational breast cancer research 16 Nov 2023 The Institute of Cancer Research, London, has been granted the highest national honour in UK further and higher education for its innovative work on breast cancer - a Queen's Anniversary Prize Find out more Show/Hide
Scan could guide use of drugs targeting tumours’ ‘scaffold’ to improve breast cancer treatment 06 Sep 2023 Researchers have found a way to use a simple, non-invasive scan to tell whether an experimental approach to enhance treatment for breast cancer is effective. Find out more Show/Hide